391 related articles for article (PubMed ID: 21133894)
21. Macrophage inflammatory protein 1 and CCR5 as attractive therapeutic targets for HIV infection.
Kasama T; Yajima N; Matsukura S; Adachi M
Recent Pat Antiinfect Drug Discov; 2006 Nov; 1(3):275-80. PubMed ID: 18221152
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
[TBL] [Abstract][Full Text] [Related]
23. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
24. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.
Nibbs RJ; Yang J; Landau NR; Mao JH; Graham GJ
J Biol Chem; 1999 Jun; 274(25):17478-83. PubMed ID: 10364178
[TBL] [Abstract][Full Text] [Related]
25. Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5.
Leach K; Charlton SJ; Strange PG
Biochem Pharmacol; 2007 Sep; 74(6):881-90. PubMed ID: 17645873
[TBL] [Abstract][Full Text] [Related]
26. Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression.
Fischer FR; Santambrogio L; Luo Y; Berman MA; Hancock WW; Dorf ME
J Neuroimmunol; 2000 Oct; 110(1-2):195-208. PubMed ID: 11024550
[TBL] [Abstract][Full Text] [Related]
27. Anti-MIP-1alpha and anti-RANTES antibodies: new allies of HIV-1?
Kissler S; Süsal C; Opelz G
Clin Immunol Immunopathol; 1997 Sep; 84(3):338-41. PubMed ID: 9281393
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological characterization of the chemokine receptor, CCR5.
Mueller A; Mahmoud NG; Goedecke MC; McKeating JA; Strange PG
Br J Pharmacol; 2002 Feb; 135(4):1033-43. PubMed ID: 11861332
[TBL] [Abstract][Full Text] [Related]
29. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
Maeda Y; Foda M; Matsushita S; Harada S
J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
[TBL] [Abstract][Full Text] [Related]
30. Bovine immunodeficiency virus expression in vitro is reduced in the presence of beta-chemokines, MIP-1alpha, MIP-1beta and RANTES.
Wright SM; Mleczko A; Coats KS
Vet Res Commun; 2002 Apr; 26(3):239-50. PubMed ID: 12090295
[TBL] [Abstract][Full Text] [Related]
31. Chemokine receptor CCR5 deficiency exacerbates cerulein-induced acute pancreatitis in mice.
Moreno C; Nicaise C; Gustot T; Quertinmont E; Nagy N; Parmentier M; Louis H; Devière J
Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1089-99. PubMed ID: 16891300
[TBL] [Abstract][Full Text] [Related]
32. CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium.
Yamagami S; Hamrah P; Miyamoto K; Miyazaki D; Dekaris I; Dawson T; Lu B; Gerard C; Dana MR
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1201-7. PubMed ID: 15790880
[TBL] [Abstract][Full Text] [Related]
33. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
[TBL] [Abstract][Full Text] [Related]
34. CC Chemokine Receptor 5 Targeted Nanoparticles Imaging the Progression and Regression of Atherosclerosis Using Positron Emission Tomography/Computed Tomography.
Detering L; Abdilla A; Luehmann HP; Williams JW; Huang LH; Sultan D; Elvington A; Heo GS; Woodard PK; Gropler RJ; Randolph GJ; Hawker CJ; Liu Y
Mol Pharm; 2021 Mar; 18(3):1386-1396. PubMed ID: 33591187
[TBL] [Abstract][Full Text] [Related]
35. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
[TBL] [Abstract][Full Text] [Related]
36. The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts.
Solomon MF; Kuziel WA; Simeonovic CJ
Cell Transplant; 2004; 13(5):503-14. PubMed ID: 15565863
[TBL] [Abstract][Full Text] [Related]
37. Chemokines as natural HIV antagonists.
Verani A; Lusso P
Curr Mol Med; 2002 Dec; 2(8):691-702. PubMed ID: 12462390
[TBL] [Abstract][Full Text] [Related]
38. Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro.
Saha K; Bentsman G; Chess L; Volsky DJ
J Virol; 1998 Jan; 72(1):876-81. PubMed ID: 9420304
[TBL] [Abstract][Full Text] [Related]
39. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor.
Honczarenko M; Le Y; Glodek AM; Majka M; Campbell JJ; Ratajczak MZ; Silberstein LE
Blood; 2002 Oct; 100(7):2321-9. PubMed ID: 12239139
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1alpha-binding activity.
Meta A; Torigoe N; Ito Y; Arakaki R; Nakashima H; Sugimura K
Mol Immunol; 1999 Dec; 36(18):1249-54. PubMed ID: 10684964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
